nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—bone cancer—peripheral nervous system neoplasm	0.165	0.374	CtDrD
Methotrexate—muscle cancer—peripheral nervous system neoplasm	0.146	0.33	CtDrD
Methotrexate—germ cell cancer—peripheral nervous system neoplasm	0.131	0.296	CtDrD
Methotrexate—ABCB1—peripheral nervous system neoplasm	0.0781	1	CbGaD
Methotrexate—PGD—Dacarbazine—peripheral nervous system neoplasm	0.0741	0.235	CbGbCtD
Methotrexate—ABCC10—Vincristine—peripheral nervous system neoplasm	0.0227	0.0721	CbGbCtD
Methotrexate—ABCC10—Etoposide—peripheral nervous system neoplasm	0.0208	0.066	CbGbCtD
Methotrexate—ABCC3—Vincristine—peripheral nervous system neoplasm	0.0143	0.0453	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—peripheral nervous system neoplasm	0.0142	0.0452	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—peripheral nervous system neoplasm	0.0142	0.045	CbGbCtD
Methotrexate—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0137	0.0436	CbGbCtD
Methotrexate—ABCC3—Cisplatin—peripheral nervous system neoplasm	0.0133	0.0423	CbGbCtD
Methotrexate—ABCC3—Etoposide—peripheral nervous system neoplasm	0.0131	0.0415	CbGbCtD
Methotrexate—ABCC1—Epirubicin—peripheral nervous system neoplasm	0.0103	0.0327	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.00953	0.0302	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—peripheral nervous system neoplasm	0.00893	0.0283	CbGbCtD
Methotrexate—ABCC1—Vincristine—peripheral nervous system neoplasm	0.00877	0.0278	CbGbCtD
Methotrexate—ABCC1—Etoposide—peripheral nervous system neoplasm	0.00804	0.0255	CbGbCtD
Methotrexate—ABCC2—Vincristine—peripheral nervous system neoplasm	0.00649	0.0206	CbGbCtD
Methotrexate—ABCC2—Cisplatin—peripheral nervous system neoplasm	0.00605	0.0192	CbGbCtD
Methotrexate—ABCC2—Etoposide—peripheral nervous system neoplasm	0.00595	0.0189	CbGbCtD
Methotrexate—ABCG2—Vincristine—peripheral nervous system neoplasm	0.00587	0.0186	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—peripheral nervous system neoplasm	0.00548	0.0174	CbGbCtD
Methotrexate—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.00547	0.0174	CbGbCtD
Methotrexate—ABCG2—Etoposide—peripheral nervous system neoplasm	0.00538	0.0171	CbGbCtD
Methotrexate—ABCB1—Topotecan—peripheral nervous system neoplasm	0.00496	0.0157	CbGbCtD
Methotrexate—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.00496	0.0157	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—peripheral nervous system neoplasm	0.00406	0.0129	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00367	0.0116	CbGbCtD
Methotrexate—ATIC—pes—peripheral nervous system neoplasm	0.00367	0.189	CbGeAlD
Methotrexate—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00344	0.0109	CbGbCtD
Methotrexate—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00212	0.00671	CbGbCtD
Methotrexate—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00197	0.00626	CbGbCtD
Methotrexate—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00194	0.00615	CbGbCtD
Methotrexate—ATIC—forelimb—peripheral nervous system neoplasm	0.00186	0.0958	CbGeAlD
Methotrexate—SLC19A1—tongue—peripheral nervous system neoplasm	0.00154	0.0795	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00132	0.0042	CbGbCtD
Methotrexate—ATIC—ganglion—peripheral nervous system neoplasm	0.001	0.0518	CbGeAlD
Methotrexate—SLCO1C1—ganglion—peripheral nervous system neoplasm	0.000833	0.043	CbGeAlD
Methotrexate—FOLR1—parotid gland—peripheral nervous system neoplasm	0.000822	0.0424	CbGeAlD
Methotrexate—MTHFR—ganglion—peripheral nervous system neoplasm	0.000745	0.0385	CbGeAlD
Methotrexate—GGH—trigeminal ganglion—peripheral nervous system neoplasm	0.000579	0.0299	CbGeAlD
Methotrexate—GGH—parotid gland—peripheral nervous system neoplasm	0.000546	0.0282	CbGeAlD
Methotrexate—FPGS—trigeminal ganglion—peripheral nervous system neoplasm	0.000509	0.0263	CbGeAlD
Methotrexate—SLCO4C1—parotid gland—peripheral nervous system neoplasm	0.000484	0.025	CbGeAlD
Methotrexate—ATIC—brainstem—peripheral nervous system neoplasm	0.000436	0.0225	CbGeAlD
Methotrexate—FOLR1—cerebellum—peripheral nervous system neoplasm	0.00038	0.0196	CbGeAlD
Methotrexate—MTHFR—trigeminal ganglion—peripheral nervous system neoplasm	0.000366	0.0189	CbGeAlD
Methotrexate—SLCO3A1—trigeminal ganglion—peripheral nervous system neoplasm	0.00036	0.0186	CbGeAlD
Methotrexate—SLC19A1—cerebellum—peripheral nervous system neoplasm	0.000333	0.0172	CbGeAlD
Methotrexate—DHFR—trigeminal ganglion—peripheral nervous system neoplasm	0.000331	0.0171	CbGeAlD
Methotrexate—PGD—trigeminal ganglion—peripheral nervous system neoplasm	0.000318	0.0164	CbGeAlD
Methotrexate—PGD—parotid gland—peripheral nervous system neoplasm	0.0003	0.0155	CbGeAlD
Methotrexate—AOX1—trigeminal ganglion—peripheral nervous system neoplasm	0.00028	0.0145	CbGeAlD
Methotrexate—ABCC10—trigeminal ganglion—peripheral nervous system neoplasm	0.000273	0.0141	CbGeAlD
Methotrexate—TYMS—Vitamin A—Tretinoin—peripheral nervous system neoplasm	0.000271	0.134	CbGdCrCtD
Methotrexate—TYMS—Vitamin A—Isotretinoin—peripheral nervous system neoplasm	0.000271	0.134	CbGdCrCtD
Methotrexate—ABCC10—parotid gland—peripheral nervous system neoplasm	0.000257	0.0133	CbGeAlD
Methotrexate—SLC46A1—cerebellum—peripheral nervous system neoplasm	0.000257	0.0133	CbGeAlD
Methotrexate—GGH—cerebellum—peripheral nervous system neoplasm	0.000253	0.013	CbGeAlD
Methotrexate—SLC22A8—trigeminal ganglion—peripheral nervous system neoplasm	0.000224	0.0116	CbGeAlD
Methotrexate—FPGS—cerebellum—peripheral nervous system neoplasm	0.000222	0.0115	CbGeAlD
Methotrexate—ATIC—cerebellum—peripheral nervous system neoplasm	0.000215	0.0111	CbGeAlD
Methotrexate—TYMS—Vitamin A—Alitretinoin—peripheral nervous system neoplasm	0.000206	0.102	CbGdCrCtD
Methotrexate—TYMS—Isotretinoin—Tretinoin—peripheral nervous system neoplasm	0.00019	0.0937	CbGdCrCtD
Methotrexate—TYMS—Tretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00019	0.0937	CbGdCrCtD
Methotrexate—TYMS—Alitretinoin—Tretinoin—peripheral nervous system neoplasm	0.00019	0.0937	CbGdCrCtD
Methotrexate—TYMS—Alitretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00019	0.0937	CbGdCrCtD
Methotrexate—ABCC1—parotid gland—peripheral nervous system neoplasm	0.000182	0.00939	CbGeAlD
Methotrexate—MTHFR—cerebellum—peripheral nervous system neoplasm	0.00016	0.00824	CbGeAlD
Methotrexate—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.00016	0.00824	CbGeAlD
Methotrexate—SLCO3A1—cerebellum—peripheral nervous system neoplasm	0.000157	0.00811	CbGeAlD
Methotrexate—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000151	0.00777	CbGeAlD
Methotrexate—TYMS—cerebellum—peripheral nervous system neoplasm	0.000146	0.00752	CbGeAlD
Methotrexate—DHFR—cerebellum—peripheral nervous system neoplasm	0.000144	0.00745	CbGeAlD
Methotrexate—TYMS—Tretinoin—Alitretinoin—peripheral nervous system neoplasm	0.000144	0.071	CbGdCrCtD
Methotrexate—TYMS—Isotretinoin—Alitretinoin—peripheral nervous system neoplasm	0.000144	0.071	CbGdCrCtD
Methotrexate—PGD—cerebellum—peripheral nervous system neoplasm	0.000139	0.00716	CbGeAlD
Methotrexate—SLC16A1—cerebellum—peripheral nervous system neoplasm	0.000129	0.00669	CbGeAlD
Methotrexate—AOX1—cerebellum—peripheral nervous system neoplasm	0.000122	0.00631	CbGeAlD
Methotrexate—ABCC10—cerebellum—peripheral nervous system neoplasm	0.000119	0.00614	CbGeAlD
Methotrexate—SLCO1A2—cerebellum—peripheral nervous system neoplasm	0.000103	0.00529	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vincristine—peripheral nervous system neoplasm	8.53e-05	0.0421	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Etoposide—peripheral nervous system neoplasm	8.52e-05	0.0421	CbGdCrCtD
Methotrexate—ABCC1—cerebellum—peripheral nervous system neoplasm	8.41e-05	0.00434	CbGeAlD
Methotrexate—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	7.87e-05	0.00406	CbGeAlD
Methotrexate—ABCG2—cerebellum—peripheral nervous system neoplasm	6.96e-05	0.0036	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vincristine—peripheral nervous system neoplasm	5.87e-05	0.029	CbGdCrCtD
Methotrexate—ABCB1—cerebellum—peripheral nervous system neoplasm	3.43e-05	0.00177	CbGeAlD
Methotrexate—Ataxia—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000256	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—peripheral nervous system neoplasm	2.92e-05	0.000256	CcSEcCtD
Methotrexate—Nausea—Melphalan—peripheral nervous system neoplasm	2.92e-05	0.000256	CcSEcCtD
Methotrexate—Asthma—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000254	CcSEcCtD
Methotrexate—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	2.89e-05	0.000253	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	2.89e-05	0.000253	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	2.88e-05	0.000252	CcSEcCtD
Methotrexate—Abdominal pain—Vincristine—peripheral nervous system neoplasm	2.88e-05	0.000252	CcSEcCtD
Methotrexate—Body temperature increased—Vincristine—peripheral nervous system neoplasm	2.88e-05	0.000252	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	2.87e-05	0.000251	CcSEcCtD
Methotrexate—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	2.87e-05	0.000251	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—peripheral nervous system neoplasm	2.86e-05	0.000251	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	2.85e-05	0.00025	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	2.85e-05	0.000249	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	0.000246	CcSEcCtD
Methotrexate—Anorexia—Etoposide—peripheral nervous system neoplasm	2.81e-05	0.000246	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	2.8e-05	0.000245	CcSEcCtD
Methotrexate—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	2.8e-05	0.000245	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	2.79e-05	0.000244	CcSEcCtD
Methotrexate—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	2.78e-05	0.000244	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	2.78e-05	0.000243	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	2.76e-05	0.000242	CcSEcCtD
Methotrexate—Hypotension—Etoposide—peripheral nervous system neoplasm	2.76e-05	0.000241	CcSEcCtD
Methotrexate—Pain—Cisplatin—peripheral nervous system neoplasm	2.75e-05	0.000241	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000238	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000238	CcSEcCtD
Methotrexate—Asthenia—Alitretinoin—peripheral nervous system neoplasm	2.71e-05	0.000237	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	2.7e-05	0.000236	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—peripheral nervous system neoplasm	2.69e-05	0.000235	CcSEcCtD
Methotrexate—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	2.68e-05	0.000235	CcSEcCtD
Methotrexate—Pruritus—Alitretinoin—peripheral nervous system neoplasm	2.67e-05	0.000234	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	2.66e-05	0.000233	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	2.65e-05	0.000232	CcSEcCtD
Methotrexate—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	2.65e-05	0.000232	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—peripheral nervous system neoplasm	2.65e-05	0.000232	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	0.000231	CcSEcCtD
Methotrexate—Dyspnoea—Etoposide—peripheral nervous system neoplasm	2.63e-05	0.00023	CcSEcCtD
Methotrexate—Somnolence—Etoposide—peripheral nervous system neoplasm	2.62e-05	0.000229	CcSEcCtD
Methotrexate—Asthenia—Vincristine—peripheral nervous system neoplasm	2.61e-05	0.000229	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000228	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	2.59e-05	0.000227	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—peripheral nervous system neoplasm	2.59e-05	0.000227	CcSEcCtD
Methotrexate—Infestation—Epirubicin—peripheral nervous system neoplasm	2.59e-05	0.000227	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—peripheral nervous system neoplasm	2.59e-05	0.000227	CcSEcCtD
Methotrexate—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	2.58e-05	0.000226	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	2.57e-05	0.000225	CcSEcCtD
Methotrexate—Rash—Dactinomycin—peripheral nervous system neoplasm	2.57e-05	0.000225	CcSEcCtD
Methotrexate—Decreased appetite—Etoposide—peripheral nervous system neoplasm	2.56e-05	0.000224	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	0.000224	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—peripheral nervous system neoplasm	2.55e-05	0.000223	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	2.55e-05	0.000223	CcSEcCtD
Methotrexate—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	2.54e-05	0.000223	CcSEcCtD
Methotrexate—Fatigue—Etoposide—peripheral nervous system neoplasm	2.54e-05	0.000223	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—peripheral nervous system neoplasm	2.53e-05	0.000221	CcSEcCtD
Methotrexate—Pain—Etoposide—peripheral nervous system neoplasm	2.52e-05	0.000221	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	2.52e-05	0.000221	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	0.00022	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	0.00022	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000219	CcSEcCtD
Methotrexate—Dizziness—Alitretinoin—peripheral nervous system neoplasm	2.5e-05	0.000219	CcSEcCtD
Methotrexate—Diarrhoea—Vincristine—peripheral nervous system neoplasm	2.49e-05	0.000218	CcSEcCtD
Methotrexate—Sweating—Epirubicin—peripheral nervous system neoplasm	2.48e-05	0.000217	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—peripheral nervous system neoplasm	2.47e-05	0.000216	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	2.45e-05	0.000215	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	2.45e-05	0.000215	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—peripheral nervous system neoplasm	2.44e-05	0.000214	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	2.43e-05	0.000213	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—peripheral nervous system neoplasm	2.42e-05	0.000212	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	2.42e-05	0.000212	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	2.41e-05	0.000211	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	2.41e-05	0.000211	CcSEcCtD
Methotrexate—Dizziness—Vincristine—peripheral nervous system neoplasm	2.41e-05	0.000211	CcSEcCtD
Methotrexate—Vomiting—Alitretinoin—peripheral nervous system neoplasm	2.4e-05	0.00021	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	0.00021	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	0.00021	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	0.00021	CcSEcCtD
Methotrexate—Rash—Alitretinoin—peripheral nervous system neoplasm	2.38e-05	0.000208	CcSEcCtD
Methotrexate—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	2.38e-05	0.000208	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	2.38e-05	0.000208	CcSEcCtD
Methotrexate—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	2.37e-05	0.000208	CcSEcCtD
Methotrexate—Headache—Alitretinoin—peripheral nervous system neoplasm	2.37e-05	0.000207	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—peripheral nervous system neoplasm	2.36e-05	0.000206	CcSEcCtD
Methotrexate—Urticaria—Etoposide—peripheral nervous system neoplasm	2.34e-05	0.000205	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	2.34e-05	0.000205	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	0.000205	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—peripheral nervous system neoplasm	2.33e-05	0.000204	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—peripheral nervous system neoplasm	2.33e-05	0.000204	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	0.000204	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	2.33e-05	0.000204	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—peripheral nervous system neoplasm	2.33e-05	0.000204	CcSEcCtD
Methotrexate—Vomiting—Vincristine—peripheral nervous system neoplasm	2.31e-05	0.000203	CcSEcCtD
Methotrexate—Asthenia—Cisplatin—peripheral nervous system neoplasm	2.31e-05	0.000202	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	2.31e-05	0.000202	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—peripheral nervous system neoplasm	2.3e-05	0.000201	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	2.3e-05	0.000201	CcSEcCtD
Methotrexate—Rash—Vincristine—peripheral nervous system neoplasm	2.29e-05	0.000201	CcSEcCtD
Methotrexate—Dermatitis—Vincristine—peripheral nervous system neoplasm	2.29e-05	0.000201	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	0.0002	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	2.28e-05	0.0002	CcSEcCtD
Methotrexate—Headache—Vincristine—peripheral nervous system neoplasm	2.28e-05	0.0002	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	0.000199	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	0.000198	CcSEcCtD
Methotrexate—Nausea—Alitretinoin—peripheral nervous system neoplasm	2.24e-05	0.000196	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—peripheral nervous system neoplasm	2.24e-05	0.000196	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	0.000196	CcSEcCtD
Methotrexate—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	2.2e-05	0.000193	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	2.2e-05	0.000193	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—peripheral nervous system neoplasm	2.17e-05	0.00019	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	2.17e-05	0.00019	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—peripheral nervous system neoplasm	2.17e-05	0.00019	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	2.16e-05	0.000189	CcSEcCtD
Methotrexate—Nausea—Vincristine—peripheral nervous system neoplasm	2.16e-05	0.000189	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	2.16e-05	0.000189	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	0.000188	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	0.000188	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	2.14e-05	0.000187	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	0.000186	CcSEcCtD
Methotrexate—Asthenia—Etoposide—peripheral nervous system neoplasm	2.12e-05	0.000185	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—peripheral nervous system neoplasm	2.11e-05	0.000185	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	0.000185	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	2.1e-05	0.000184	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	2.1e-05	0.000184	CcSEcCtD
Methotrexate—Chills—Epirubicin—peripheral nervous system neoplasm	2.09e-05	0.000183	CcSEcCtD
Methotrexate—Pruritus—Etoposide—peripheral nervous system neoplasm	2.09e-05	0.000183	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	0.000182	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—peripheral nervous system neoplasm	2.06e-05	0.00018	CcSEcCtD
Methotrexate—Vomiting—Cisplatin—peripheral nervous system neoplasm	2.05e-05	0.000179	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—peripheral nervous system neoplasm	2.04e-05	0.000178	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	2.04e-05	0.000178	CcSEcCtD
Methotrexate—Rash—Cisplatin—peripheral nervous system neoplasm	2.03e-05	0.000178	CcSEcCtD
Methotrexate—Dermatitis—Cisplatin—peripheral nervous system neoplasm	2.03e-05	0.000177	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—peripheral nervous system neoplasm	2.03e-05	0.000177	CcSEcCtD
Methotrexate—Erythema—Epirubicin—peripheral nervous system neoplasm	2.03e-05	0.000177	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—peripheral nervous system neoplasm	2.02e-05	0.000177	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	0.000176	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	0.000176	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	2e-05	0.000175	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	1.98e-05	0.000174	CcSEcCtD
Methotrexate—Back pain—Epirubicin—peripheral nervous system neoplasm	1.96e-05	0.000171	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	1.95e-05	0.000171	CcSEcCtD
Methotrexate—Dizziness—Etoposide—peripheral nervous system neoplasm	1.95e-05	0.000171	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	0.00017	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	0.00017	CcSEcCtD
Methotrexate—Chills—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	0.000169	CcSEcCtD
Methotrexate—Nausea—Cisplatin—peripheral nervous system neoplasm	1.91e-05	0.000167	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—peripheral nervous system neoplasm	1.91e-05	0.000167	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—peripheral nervous system neoplasm	1.9e-05	0.000167	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	1.89e-05	0.000165	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	1.88e-05	0.000164	CcSEcCtD
Methotrexate—Vomiting—Etoposide—peripheral nervous system neoplasm	1.87e-05	0.000164	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—peripheral nervous system neoplasm	1.87e-05	0.000164	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	1.87e-05	0.000164	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—peripheral nervous system neoplasm	1.87e-05	0.000164	CcSEcCtD
Methotrexate—Rash—Etoposide—peripheral nervous system neoplasm	1.86e-05	0.000163	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—peripheral nervous system neoplasm	1.86e-05	0.000163	CcSEcCtD
Methotrexate—Headache—Etoposide—peripheral nervous system neoplasm	1.85e-05	0.000162	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	1.83e-05	0.000161	CcSEcCtD
Methotrexate—Malaise—Epirubicin—peripheral nervous system neoplasm	1.83e-05	0.00016	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—peripheral nervous system neoplasm	1.82e-05	0.000159	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.000159	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—peripheral nervous system neoplasm	1.81e-05	0.000159	CcSEcCtD
Methotrexate—Cough—Epirubicin—peripheral nervous system neoplasm	1.77e-05	0.000155	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	1.77e-05	0.000155	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—peripheral nervous system neoplasm	1.75e-05	0.000154	CcSEcCtD
Methotrexate—Nausea—Etoposide—peripheral nervous system neoplasm	1.75e-05	0.000153	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	1.74e-05	0.000152	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—peripheral nervous system neoplasm	1.73e-05	0.000152	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—peripheral nervous system neoplasm	1.72e-05	0.000151	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—peripheral nervous system neoplasm	1.72e-05	0.000151	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—peripheral nervous system neoplasm	1.72e-05	0.000151	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	1.71e-05	0.00015	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—peripheral nervous system neoplasm	1.7e-05	0.000149	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—peripheral nervous system neoplasm	1.69e-05	0.000148	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.000147	CcSEcCtD
Methotrexate—PGD—Metabolism—ABCB1—peripheral nervous system neoplasm	1.68e-05	0.000599	CbGpPWpGaD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	1.68e-05	0.000599	CbGpPWpGaD
Methotrexate—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.000147	CcSEcCtD
Methotrexate—MTHFR—Disease—SLC2A1—peripheral nervous system neoplasm	1.68e-05	0.000598	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.68e-05	0.000597	CbGpPWpGaD
Methotrexate—Confusional state—Epirubicin—peripheral nervous system neoplasm	1.67e-05	0.000146	CcSEcCtD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.66e-05	0.000593	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	1.65e-05	0.000145	CcSEcCtD
Methotrexate—Infection—Epirubicin—peripheral nervous system neoplasm	1.64e-05	0.000144	CcSEcCtD
Methotrexate—AOX1—Disease—SLC2A1—peripheral nervous system neoplasm	1.64e-05	0.000584	CbGpPWpGaD
Methotrexate—Cough—Doxorubicin—peripheral nervous system neoplasm	1.64e-05	0.000143	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—peripheral nervous system neoplasm	1.62e-05	0.000142	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	1.62e-05	0.000142	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	1.62e-05	0.000142	CcSEcCtD
Methotrexate—ALB—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	1.61e-05	0.000574	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.61e-05	0.000573	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.61e-05	0.000573	CbGpPWpGaD
Methotrexate—Skin disorder—Epirubicin—peripheral nervous system neoplasm	1.61e-05	0.000141	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—HGF—peripheral nervous system neoplasm	1.6e-05	0.000571	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	1.6e-05	0.00014	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	1.6e-05	0.00014	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—peripheral nervous system neoplasm	1.6e-05	0.00014	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—peripheral nervous system neoplasm	1.6e-05	0.00014	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	1.58e-05	0.000139	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	1.58e-05	0.000565	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.58e-05	0.000563	CbGpPWpGaD
Methotrexate—Discomfort—Doxorubicin—peripheral nervous system neoplasm	1.58e-05	0.000138	CcSEcCtD
Methotrexate—FPGS—Disease—ERBB2—peripheral nervous system neoplasm	1.58e-05	0.000562	CbGpPWpGaD
Methotrexate—Anorexia—Epirubicin—peripheral nervous system neoplasm	1.58e-05	0.000138	CcSEcCtD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.57e-05	0.000562	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.57e-05	0.000559	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTPN11—peripheral nervous system neoplasm	1.55e-05	0.000554	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.55e-05	0.000552	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ENO2—peripheral nervous system neoplasm	1.55e-05	0.000552	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.55e-05	0.000552	CbGpPWpGaD
Methotrexate—Hypotension—Epirubicin—peripheral nervous system neoplasm	1.54e-05	0.000135	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—peripheral nervous system neoplasm	1.54e-05	0.000135	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.54e-05	0.000549	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	1.53e-05	0.000134	CcSEcCtD
Methotrexate—ABCC2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.53e-05	0.000544	CbGpPWpGaD
Methotrexate—Infection—Doxorubicin—peripheral nervous system neoplasm	1.52e-05	0.000133	CcSEcCtD
Methotrexate—ABCC3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.52e-05	0.000542	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.52e-05	0.000541	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.51e-05	0.000538	CbGpPWpGaD
Methotrexate—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	1.51e-05	0.000132	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.51e-05	0.000537	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	1.5e-05	0.000535	CbGpPWpGaD
Methotrexate—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	1.5e-05	0.000131	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	1.5e-05	0.000131	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—peripheral nervous system neoplasm	1.49e-05	0.000131	CcSEcCtD
Methotrexate—DHFR—Disease—SLC2A1—peripheral nervous system neoplasm	1.49e-05	0.000531	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.49e-05	0.000531	CbGpPWpGaD
Methotrexate—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	1.49e-05	0.00013	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	1.48e-05	0.00013	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.48e-05	0.000529	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	1.48e-05	0.000129	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	1.47e-05	0.000129	CcSEcCtD
Methotrexate—MTHFR—Metabolism—BCHE—peripheral nervous system neoplasm	1.47e-05	0.000525	CbGpPWpGaD
Methotrexate—Somnolence—Epirubicin—peripheral nervous system neoplasm	1.47e-05	0.000129	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	1.47e-05	0.000524	CbGpPWpGaD
Methotrexate—Anorexia—Doxorubicin—peripheral nervous system neoplasm	1.46e-05	0.000128	CcSEcCtD
Methotrexate—ABCC4—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.46e-05	0.000519	CbGpPWpGaD
Methotrexate—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	1.45e-05	0.000127	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1.45e-05	0.000517	CbGpPWpGaD
Methotrexate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	1.45e-05	0.000517	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNS—peripheral nervous system neoplasm	1.45e-05	0.000516	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.45e-05	0.000515	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—BCHE—peripheral nervous system neoplasm	1.44e-05	0.000513	CbGpPWpGaD
Methotrexate—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	1.44e-05	0.000126	CcSEcCtD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.43e-05	0.000511	CbGpPWpGaD
Methotrexate—Hypotension—Doxorubicin—peripheral nervous system neoplasm	1.43e-05	0.000125	CcSEcCtD
Methotrexate—ABCC4—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.43e-05	0.000509	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	1.43e-05	0.000125	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—peripheral nervous system neoplasm	1.42e-05	0.000125	CcSEcCtD
Methotrexate—PGD—Disease—PTPN11—peripheral nervous system neoplasm	1.42e-05	0.000507	CbGpPWpGaD
Methotrexate—Pain—Epirubicin—peripheral nervous system neoplasm	1.41e-05	0.000124	CcSEcCtD
Methotrexate—SLC19A1—Disease—NRAS—peripheral nervous system neoplasm	1.41e-05	0.000503	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.41e-05	0.000503	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.41e-05	0.000502	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	1.41e-05	0.000501	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.4e-05	0.000501	CbGpPWpGaD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	1.39e-05	0.000122	CcSEcCtD
Methotrexate—ABCC1—Metabolism—NME1—peripheral nervous system neoplasm	1.39e-05	0.000494	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—TH—peripheral nervous system neoplasm	1.38e-05	0.000493	CbGpPWpGaD
Methotrexate—Insomnia—Doxorubicin—peripheral nervous system neoplasm	1.38e-05	0.000121	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism—GNS—peripheral nervous system neoplasm	1.37e-05	0.00049	CbGpPWpGaD
Methotrexate—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	1.37e-05	0.00012	CcSEcCtD
Methotrexate—AOX1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.37e-05	0.000489	CbGpPWpGaD
Methotrexate—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	1.36e-05	0.000119	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	1.36e-05	0.000119	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—peripheral nervous system neoplasm	1.36e-05	0.000119	CcSEcCtD
Methotrexate—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.36e-05	0.000483	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—TH—peripheral nervous system neoplasm	1.35e-05	0.000482	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	1.35e-05	0.000118	CcSEcCtD
Methotrexate—TYMS—Metabolism—ENO2—peripheral nervous system neoplasm	1.35e-05	0.000482	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.35e-05	0.000481	CbGpPWpGaD
Methotrexate—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	1.35e-05	0.000118	CcSEcCtD
Methotrexate—DHFR—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	1.34e-05	0.000479	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—COX2—peripheral nervous system neoplasm	1.33e-05	0.000476	CbGpPWpGaD
Methotrexate—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	1.33e-05	0.000116	CcSEcCtD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.33e-05	0.000473	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.32e-05	0.000472	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.32e-05	0.000116	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—peripheral nervous system neoplasm	1.32e-05	0.000115	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism—NME1—peripheral nervous system neoplasm	1.32e-05	0.00047	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MYC—peripheral nervous system neoplasm	1.31e-05	0.000468	CbGpPWpGaD
Methotrexate—Urticaria—Epirubicin—peripheral nervous system neoplasm	1.31e-05	0.000115	CcSEcCtD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	1.31e-05	0.000467	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—BCHE—peripheral nervous system neoplasm	1.31e-05	0.000466	CbGpPWpGaD
Methotrexate—Pain—Doxorubicin—peripheral nervous system neoplasm	1.31e-05	0.000114	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	1.31e-05	0.000114	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	1.31e-05	0.000114	CcSEcCtD
Methotrexate—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	1.27e-05	0.000454	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.27e-05	0.000453	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—COX2—peripheral nervous system neoplasm	1.27e-05	0.000452	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.27e-05	0.000452	CbGpPWpGaD
Methotrexate—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	1.26e-05	0.00011	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	1.25e-05	0.000109	CcSEcCtD
Methotrexate—DHFR—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.25e-05	0.000445	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.24e-05	0.000443	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	1.24e-05	0.000442	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO2—peripheral nervous system neoplasm	1.24e-05	0.000442	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—TH—peripheral nervous system neoplasm	1.23e-05	0.000438	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—ERBB2—peripheral nervous system neoplasm	1.23e-05	0.000438	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.23e-05	0.000438	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	1.22e-05	0.000435	CbGpPWpGaD
Methotrexate—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.22e-05	0.000107	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.21e-05	0.000106	CcSEcCtD
Methotrexate—ABCC1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.21e-05	0.000433	CbGpPWpGaD
Methotrexate—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.21e-05	0.000106	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.21e-05	0.000106	CcSEcCtD
Methotrexate—ABCC1—Disease—PPP3R1—peripheral nervous system neoplasm	1.21e-05	0.000431	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.2e-05	0.000429	CbGpPWpGaD
Methotrexate—FPGS—Disease—NRAS—peripheral nervous system neoplasm	1.2e-05	0.000428	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.19e-05	0.000425	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.19e-05	0.000424	CbGpPWpGaD
Methotrexate—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.19e-05	0.000104	CcSEcCtD
Methotrexate—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	1.17e-05	0.000419	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	1.17e-05	0.000418	CbGpPWpGaD
Methotrexate—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.17e-05	0.000102	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.17e-05	0.000417	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.15e-05	0.000411	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—BCHE—peripheral nervous system neoplasm	1.14e-05	0.000407	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.14e-05	0.000405	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.13e-05	0.000403	CbGpPWpGaD
Methotrexate—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.13e-05	9.9e-05	CcSEcCtD
Methotrexate—MTHFR—Metabolism—GNAS—peripheral nervous system neoplasm	1.13e-05	0.000403	CbGpPWpGaD
Methotrexate—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.13e-05	9.86e-05	CcSEcCtD
Methotrexate—PGD—Disease—ERBB2—peripheral nervous system neoplasm	1.12e-05	0.0004	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—TH—peripheral nervous system neoplasm	1.12e-05	0.000399	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO2—peripheral nervous system neoplasm	1.12e-05	0.000399	CbGpPWpGaD
Methotrexate—FPGS—Disease—MYC—peripheral nervous system neoplasm	1.12e-05	0.000398	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ABCB1—peripheral nervous system neoplasm	1.11e-05	0.000395	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GNAS—peripheral nervous system neoplasm	1.1e-05	0.000393	CbGpPWpGaD
Methotrexate—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.1e-05	9.61e-05	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.09e-05	9.57e-05	CcSEcCtD
Methotrexate—TYMS—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.09e-05	0.000388	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.09e-05	0.000387	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.08e-05	0.000386	CbGpPWpGaD
Methotrexate—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.08e-05	9.47e-05	CcSEcCtD
Methotrexate—TYMS—Metabolism—TH—peripheral nervous system neoplasm	1.07e-05	0.000383	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.07e-05	0.000381	CbGpPWpGaD
Methotrexate—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.05e-05	9.2e-05	CcSEcCtD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.05e-05	0.000373	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—BCHE—peripheral nervous system neoplasm	1.05e-05	0.000373	CbGpPWpGaD
Methotrexate—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.05e-05	9.16e-05	CcSEcCtD
Methotrexate—ABCC1—Disease—ENO2—peripheral nervous system neoplasm	1.05e-05	0.000373	CbGpPWpGaD
Methotrexate—Rash—Epirubicin—peripheral nervous system neoplasm	1.04e-05	9.12e-05	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.04e-05	9.11e-05	CcSEcCtD
Methotrexate—Headache—Epirubicin—peripheral nervous system neoplasm	1.04e-05	9.06e-05	CcSEcCtD
Methotrexate—SLC19A1—Disease—HRAS—peripheral nervous system neoplasm	1.03e-05	0.000368	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	1.02e-05	0.000363	CbGpPWpGaD
Methotrexate—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.01e-05	8.85e-05	CcSEcCtD
Methotrexate—DHFR—Metabolism—GNAS—peripheral nervous system neoplasm	1e-05	0.000358	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.99e-06	0.000356	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ABCB1—peripheral nervous system neoplasm	9.85e-06	0.000351	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—TH—peripheral nervous system neoplasm	9.84e-06	0.000351	CbGpPWpGaD
Methotrexate—Nausea—Epirubicin—peripheral nervous system neoplasm	9.82e-06	8.59e-05	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism—ENO2—peripheral nervous system neoplasm	9.73e-06	0.000347	CbGpPWpGaD
Methotrexate—Vomiting—Doxorubicin—peripheral nervous system neoplasm	9.72e-06	8.51e-05	CcSEcCtD
Methotrexate—Rash—Doxorubicin—peripheral nervous system neoplasm	9.64e-06	8.44e-05	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	9.63e-06	8.43e-05	CcSEcCtD
Methotrexate—Headache—Doxorubicin—peripheral nervous system neoplasm	9.58e-06	8.39e-05	CcSEcCtD
Methotrexate—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	9.51e-06	0.000339	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—BCHE—peripheral nervous system neoplasm	9.45e-06	0.000337	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NRAS—peripheral nervous system neoplasm	9.42e-06	0.000336	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	9.39e-06	0.000335	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTPN11—peripheral nervous system neoplasm	9.37e-06	0.000334	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NRAS—peripheral nervous system neoplasm	9.34e-06	0.000333	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	9.18e-06	0.000327	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTPN11—peripheral nervous system neoplasm	9.16e-06	0.000326	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GNAS—peripheral nervous system neoplasm	9.14e-06	0.000326	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—AKT1—peripheral nervous system neoplasm	9.11e-06	0.000325	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MYC—peripheral nervous system neoplasm	9.09e-06	0.000324	CbGpPWpGaD
Methotrexate—Nausea—Doxorubicin—peripheral nervous system neoplasm	9.08e-06	7.95e-05	CcSEcCtD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	9.02e-06	0.000322	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.01e-06	0.000321	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ABCB1—peripheral nervous system neoplasm	8.97e-06	0.00032	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TH—peripheral nervous system neoplasm	8.88e-06	0.000317	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	8.87e-06	0.000316	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	8.8e-06	0.000314	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—peripheral nervous system neoplasm	8.77e-06	0.000313	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO2—peripheral nervous system neoplasm	8.76e-06	0.000312	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GNAS—peripheral nervous system neoplasm	8.76e-06	0.000312	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MYC—peripheral nervous system neoplasm	8.7e-06	0.00031	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	8.7e-06	0.00031	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ABCB1—peripheral nervous system neoplasm	8.6e-06	0.000306	CbGpPWpGaD
Methotrexate—PGD—Disease—NRAS—peripheral nervous system neoplasm	8.54e-06	0.000305	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SLC2A1—peripheral nervous system neoplasm	8.43e-06	0.000301	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTPN11—peripheral nervous system neoplasm	8.33e-06	0.000297	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO2—peripheral nervous system neoplasm	8.32e-06	0.000297	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.23e-06	0.000293	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	8.19e-06	0.000292	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GNAS—peripheral nervous system neoplasm	8.04e-06	0.000287	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	7.98e-06	0.000285	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—peripheral nervous system neoplasm	7.96e-06	0.000284	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—peripheral nervous system neoplasm	7.94e-06	0.000283	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ABCB1—peripheral nervous system neoplasm	7.88e-06	0.000281	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNS—peripheral nervous system neoplasm	7.85e-06	0.00028	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.85e-06	0.00028	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—peripheral nervous system neoplasm	7.74e-06	0.000276	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TH—peripheral nervous system neoplasm	7.73e-06	0.000276	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	7.71e-06	0.000275	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—peripheral nervous system neoplasm	7.63e-06	0.000272	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	7.61e-06	0.000271	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NME1—peripheral nervous system neoplasm	7.53e-06	0.000268	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—peripheral nervous system neoplasm	7.47e-06	0.000266	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERBB2—peripheral nervous system neoplasm	7.41e-06	0.000264	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—BCHE—peripheral nervous system neoplasm	7.4e-06	0.000264	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GNAS—peripheral nervous system neoplasm	7.25e-06	0.000259	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	7.25e-06	0.000258	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	7.24e-06	0.000258	CbGpPWpGaD
Methotrexate—ALB—Metabolism—COX2—peripheral nervous system neoplasm	7.24e-06	0.000258	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERBB2—peripheral nervous system neoplasm	7.24e-06	0.000258	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—peripheral nervous system neoplasm	7.21e-06	0.000257	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.17e-06	0.000256	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ABCB1—peripheral nervous system neoplasm	7.11e-06	0.000254	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.06e-06	0.000252	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—BCHE—peripheral nervous system neoplasm	7.03e-06	0.000251	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NRAS—peripheral nervous system neoplasm	7.03e-06	0.000251	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TH—peripheral nervous system neoplasm	6.96e-06	0.000248	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—peripheral nervous system neoplasm	6.89e-06	0.000246	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	6.88e-06	0.000245	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—peripheral nervous system neoplasm	6.83e-06	0.000244	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.71e-06	0.000239	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TH—peripheral nervous system neoplasm	6.61e-06	0.000236	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	6.59e-06	0.000235	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.59e-06	0.000235	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB2—peripheral nervous system neoplasm	6.58e-06	0.000235	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—peripheral nervous system neoplasm	6.52e-06	0.000232	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	6.51e-06	0.000232	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—peripheral nervous system neoplasm	6.49e-06	0.000231	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—peripheral nervous system neoplasm	6.49e-06	0.000231	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.46e-06	0.00023	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	6.35e-06	0.000226	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.31e-06	0.000225	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—peripheral nervous system neoplasm	6.25e-06	0.000223	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.21e-06	0.000222	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.19e-06	0.000221	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	6.12e-06	0.000218	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—peripheral nervous system neoplasm	6.09e-06	0.000217	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—peripheral nervous system neoplasm	6.03e-06	0.000215	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.77e-06	0.000206	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNAS—peripheral nervous system neoplasm	5.68e-06	0.000203	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	5.66e-06	0.000202	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—peripheral nervous system neoplasm	5.64e-06	0.000201	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ABCB1—peripheral nervous system neoplasm	5.57e-06	0.000199	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—peripheral nervous system neoplasm	5.52e-06	0.000197	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—peripheral nervous system neoplasm	5.51e-06	0.000196	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GNAS—peripheral nervous system neoplasm	5.4e-06	0.000193	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—peripheral nervous system neoplasm	5.37e-06	0.000192	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	5.3e-06	0.000189	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	5.29e-06	0.000189	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—peripheral nervous system neoplasm	5.25e-06	0.000187	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—peripheral nervous system neoplasm	5.14e-06	0.000183	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—peripheral nervous system neoplasm	5.13e-06	0.000183	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—peripheral nervous system neoplasm	5.05e-06	0.00018	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—peripheral nervous system neoplasm	5.01e-06	0.000179	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	5e-06	0.000178	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.91e-06	0.000175	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	4.76e-06	0.00017	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTPN11—peripheral nervous system neoplasm	4.71e-06	0.000168	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—peripheral nervous system neoplasm	4.67e-06	0.000166	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	4.65e-06	0.000166	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—peripheral nervous system neoplasm	4.62e-06	0.000165	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—peripheral nervous system neoplasm	4.54e-06	0.000162	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	4.17e-06	0.000149	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—peripheral nervous system neoplasm	4.12e-06	0.000147	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—peripheral nervous system neoplasm	4.03e-06	0.000144	CbGpPWpGaD
Methotrexate—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	4.02e-06	0.000143	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	3.98e-06	0.000142	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.92e-06	0.00014	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.83e-06	0.000137	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TH—peripheral nervous system neoplasm	3.78e-06	0.000135	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—peripheral nervous system neoplasm	3.73e-06	0.000133	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—peripheral nervous system neoplasm	3.66e-06	0.000131	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—peripheral nervous system neoplasm	3.64e-06	0.00013	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—peripheral nervous system neoplasm	3.56e-06	0.000127	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	3.52e-06	0.000126	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.36e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	3.31e-06	0.000118	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—peripheral nervous system neoplasm	3.24e-06	0.000115	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	3.18e-06	0.000113	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	3.08e-06	0.00011	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—peripheral nervous system neoplasm	3.05e-06	0.000109	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	3.03e-06	0.000108	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—peripheral nervous system neoplasm	2.98e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—peripheral nervous system neoplasm	2.83e-06	0.000101	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—peripheral nervous system neoplasm	2.71e-06	9.66e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	2.7e-06	9.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—peripheral nervous system neoplasm	2.64e-06	9.41e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.47e-06	8.8e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	2.43e-06	8.67e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—peripheral nervous system neoplasm	2.36e-06	8.43e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	2.33e-06	8.29e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—peripheral nervous system neoplasm	2.17e-06	7.73e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—peripheral nervous system neoplasm	2.07e-06	7.39e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	2.05e-06	7.32e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—peripheral nervous system neoplasm	1.96e-06	6.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—peripheral nervous system neoplasm	1.83e-06	6.53e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.7e-06	6.08e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—peripheral nervous system neoplasm	1.53e-06	5.47e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—peripheral nervous system neoplasm	1.46e-06	5.2e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.35e-06	4.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	8.33e-07	2.97e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	7.29e-07	2.6e-05	CbGpPWpGaD
